NeuroSense Therapeutics Reports $2.10 Loss Per Share, Beating Analyst Estimates

Key Facts

1NeuroSense Therapeutics reported a GAAP EPS of -$2.10, beating analyst estimates by $1.83.

NeuroSense Therapeutics reported a GAAP loss per share of $2.10, beating analyst estimates by $1.83. Seeking Alpha reported that operating expenses for the six months ended June 30, 2026, were $3.4 million, down from $4.7 million in the same period of 2025.

NRSN closed at $7.4 on September 24, 2026, with the stock trading between a day low of $6.93 and a high of $7.4 during that session. These financial results reflect a significant beat against market expectations despite the company remaining in a loss-making position.